Mixed results from scheduling committee

Asthma combination medication to remain a prescription product, but new anti-histamine to be downscheduled, as latest scheduling decisions are released A proposal to downschedule the asthma combination medicine containing budesonide and formoterol has been rejected by the Therapeutic Goods Administration's Advisory Committee on Medicines Scheduling (ACMS). The results of the November hearing of the ACMS